BERG Presents First-In-Kind Data Using Its Bayesian AI-Driven Interrogative Biology® Technology To Map Underlying Biology Of Patient Responses In Advanced Solid Tumor Trial Of BPM31510
FRAMINGHAM, Mass., Sept. 28, 2019 /PRNewswire/ — BERG, a clinical stage biopharmaceutical company that utilizes artificial intelligence (AI) and multi-omics to identify novel biology and disease modifying targets, today announced results from a predictive analysis of adverse events by…
Comments Off on BERG Presents First-In-Kind Data Using Its Bayesian AI-Driven Interrogative Biology® Technology To Map Underlying Biology Of Patient Responses In Advanced Solid Tumor Trial Of BPM31510